Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Cytotoxic Edema: Pathophysiology

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Cellular Injury IV: Necrosis

Cellular Injury IV: Necrosis

Necrosis is a form of irreversible cell death caused by severe injury such as ischemia, toxins, or trauma. Unlike programmed cell death, it is an uncontrolled, pathological process that typically provokes inflammation in surrounding tissues.Pathophysiologic ChangesNecrosis begins when cells sustain critical damage, leading to swelling of organelles, particularly mitochondria, and rapid ATP depletion. As energy levels decline, membrane ion pumps fail, leading to calcium influx and eventually,...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multi-modal AI for comprehensive breast cancer prognostication.

Nature communications·2026

Same author

Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results.

NPJ breast cancer·2026

Same author

Functional germline variants together with somatic mutations alter the integrity of cancer hallmark regulatory networks.

Genome medicine·2026

Same author

The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.

JNCI cancer spectrum·2026

Same author

ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.

Annals of surgical oncology·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Paclitaxel-induced sickle cell crisis.

Nicole M Wilson¹, Janet L Espirito, Vicente Valero

¹Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA. nmwilson@butler.edu [corrected]

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists

|July 3, 2008

Summary

This case report details a painful crisis in a breast cancer patient with sickle cell disease (SCD) triggered by paclitaxel chemotherapy. This highlights a critical drug-induced complication in patients with co-existing SCD.

More Related Videos

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jul 4, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Breast cancer management often involves chemotherapy.
Sickle cell disease (SCD) is a genetic blood disorder.
Paclitaxel is a common chemotherapy agent.

Observation:

A patient with breast cancer and undiagnosed sickle cell disease (SCD) developed severe pain and hemolysis.
Symptoms emerged after initiating paclitaxel chemotherapy.
The patient had no prior history of sickle cell crises.

Findings:

Paclitaxel chemotherapy precipitated a painful crisis in a patient with sickle cell disease (SCD).
Hemolysis was a key laboratory finding during the crisis.
The patient required hospitalization and supportive care for the crisis.

Implications:

Clinicians should consider SCD in patients presenting with unexplained painful crises during paclitaxel treatment.
Screening for hemoglobinopathies may be warranted in at-risk populations undergoing chemotherapy.
Understanding drug-induced complications in patients with co-existing conditions is crucial for safe treatment.